Funding Archives

News and Trends 23 Aug 2022

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

BioInnovation Institute launches new program and takes on four companies

The BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating life science research, says four companies have joined its new Venture House program. Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of €1.3 million ($1.3 million). […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Constructive Bio launches with $15M seed investment to re-engineer biology

A biotech company has launched in the UK after securing a deal that includes intellectual property re-engineering biology by creating new classes of enzymes, pharmaceuticals and biomaterials. Constructive Bio has completed a $15 million (€15 million) seed round and gained an exclusive license from the Medical Research Council to intellectual property (IP) developed by Professor […]

August 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Aug 2022

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

The National Institute of Allergy and Infectious Disease (NIAID) has awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes hepatitis C. Hepatitis C is an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus (HCV) […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Aug 2022

BioInnovation Institute supports three start-ups

The BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating life science research, has invested in three international start-up companies in the U.K., Germany, and Finland. The three new ventures are strategically aligned with the BII’s focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space. Each company will be funded […]

August 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

Emtora to use $16.9M grant to develop treatment for rare genetic disease

Emtora Biosciences, a Texas-based clinical-stage biopharmaceutical company, has been awarded a $16.9 million non-dilutive grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The funding will be used to advance the clinical and product development of its lead program, eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis (FAP). […]

August 19, 2022 - 2 minutesmins - By Jim Cornall

ADC Therapeutics announces $175M loan from Owl Rock

News and Trends 16 Aug 2022

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Jul 2022

BigHat Biosciences raises $75M to design safer, more effective antibodies

A company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today (July 20) announced it has raised $75 million in funding. BigHat Biosciences’ series B funding round was led by Section 32 with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital and others. […]

July 20, 2022 - 4 minutesmins - By Liza Laws

Optics11 Life receives €5 million in funding for drug development

News and Trends 18 Jul 2022

FORTY51 Ventures closes $43M biotech fund and announces first investment

FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its first close. FORTY51’s core strategy focuses on company formation and early-stage investments in biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (seed and series A) of its growing portfolio, which will […]

July 18, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2022

Financing round of $21M completed for drug to treat autoimmune diseases

The first-round of financing to the tune of $21 million (€20.6 million), for a drug to treat autoimmune disease, has been completed between Precision Autoimmune Therapeutics (PAT) and CASI Pharmaceuticals. PAT will pay CASI a $5 million (€4.9 million) equivalent as the first instalment of the upfront payment of the sub-license agreement. In May this […]

July 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Jul 2022

Biosyntia closes a €11.5M round to launch world’s first bio-based vitamin B7

A bio-based vitamin B7 is the first product to be commercialized as biotech company, Biosyntia, secures funding from a strong syndicate of capital investors. Biosyntia, manufactures sustainable and natural ingredients using precision fermentation and has a strong pipeline of active ingredients for use in beauty and nutrition products such as vitamins and antioxidants. A funding […]

July 8, 2022 - 3 minutesmins - By Liza Laws

gastrointestinal disease heptares imperial2 1

News and Trends 7 Jul 2022

French Juvisé buys gastro product in €400M finance deal

French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […]

July 7, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Funding

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

BioInnovation Institute launches new program and takes on four companies

Constructive Bio launches with $15M seed investment to re-engineer biology

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

BioInnovation Institute supports three start-ups

Emtora to use $16.9M grant to develop treatment for rare genetic disease

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

BigHat Biosciences raises $75M to design safer, more effective antibodies

FORTY51 Ventures closes $43M biotech fund and announces first investment

Financing round of $21M completed for drug to treat autoimmune diseases

Biosyntia closes a €11.5M round to launch world’s first bio-based vitamin B7

French Juvisé buys gastro product in €400M finance deal

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!